Neosine Duo is the first combination of inosine pranobex and zinc gluconate. The product is now available in pharmacies upon presentation of a prescription written by a doctor.

Neosine Duo, in the form of a syrup, is intended for children from the very first year of life. It contains 500 mg of inosine pranobex and 3,125 mg of zinc gluconate in 5 ml of syrup. The approved therapeutic indications include use in immunocompromised patients, in case of recurrent infections of the upper respiratory tract, in conditions of increased demand for zinc, appearing in the above indication.

Inosine pranobex is a known and effective antiviral drug that supports immunity. Zinc perfectly complements and broadens the effects of inosine, and indicates anti-inflammatory properties. The combination of those two active substances provides a comprehensive effect on the immune system in the fight against infections, asserts Hanna Wahl, Research & Development Director at Aflofarm Farmacja Polska.

Immunomodulatory and anti-inflammatory effects of zinc have already been evaluated in an abundance of studies. According to WHO, every third person suffers from deficiency of this element, which results in reduced immunity and greater susceptibility to infections. What's more, the level of zinc in the body may drop further during infections. The efficacy of inosine pranobex in the treatment of respiratory viral infections has been confirmed repeatedly. Clinical studies have shown that inosine pranobex effectively reduces the symptoms of influenza, such as muscle pain, malaise, fever and rhinitis in infected individuals[1]. In prophylactic treatment, in case of recurring infections, a statistically significant increase in the number of CD3T and CD4T lymphocytes was noted along with a statistically significant improvement in their functioning. Laboratory results were in line with positive clinical effects. More than 5-fold reduction in the number of recurring respiratory infections, more than a 15-fold reduction in the number of antibiotic therapy, and over 8-fold shortening of the duration of infection have been confirmed, amongst others[2].

Respiratory viral infections comprise one of the most common health problems, especially in children. They manifest themselves as an inflammation within the throat, larynx, nose and paranasal sinuses. Infection occurs mainly in periods of reduced immunity, and thus autumn-winter and spring. The immune system is responsible for running the diagnosis, eradication and elimination of the viruses from the body. Zinc constitutes an essential element of its proper functioning. Inosine pranobex is an effective and safe substance with immunomodulatory and antiviral properties.

The Marketing Authorization for Neosine Duo, syrup, was issued on 16th October 2018, by the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. The product was released for sale in November.

Aflofarm has been operating on the prescription drug market since 1998. The Rx segment remains one of the priority directions for the company's development. Currently, Aflofarm has over a dozen product items available in the prescription segment, including drugs such as Stepcil (used to treat intermittent claudication), Cetix (third generation cephalosporin), Dafurag (the first furazidine in the form of a suspension) or Kidofen Duo (the only combination of ibuprofen and paracetamol in a pediatric form).


[1] Khakoo RA, Watson GW, Waldman RH, Ganguly R. Effect of inosiplex (Isoprinosine) on induced human influenza A infection. J Antimicrob Chemother. 1981 Apr;7(4):389-97.

[2] Gołębiowska-Wawrzyniak M, Markiewicz K, Kozar A, Derentowicz P, Czerwińska-Kartowicz I, Jastrzebska-Janas K, Wacławek J, Wawrzyniak ZM, Siwińska-Gołebiowska H. [Immunological and clinical study on therapeutic efficacy of inosine pranobex] Pol Merkur Lekarski. 2005 Sep; 19 (111):379-82.